(NASDAQ: LQDA) Liquidia's forecast annual revenue growth rate of 103.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.74%.
Liquidia's revenue in 2025 is $69,216,000.On average, 10 Wall Street analysts forecast LQDA's revenue for 2025 to be $12,234,174,774, with the lowest LQDA revenue forecast at $4,217,280,029, and the highest LQDA revenue forecast at $15,806,209,306. On average, 10 Wall Street analysts forecast LQDA's revenue for 2026 to be $35,265,358,944, with the lowest LQDA revenue forecast at $21,943,740,632, and the highest LQDA revenue forecast at $46,358,152,981.
In 2027, LQDA is forecast to generate $50,563,514,629 in revenue, with the lowest revenue forecast at $34,365,825,649 and the highest revenue forecast at $67,230,109,262.